Does PYXS pay a dividend?

The cached stock data on this page does not show a positive dividend yield for PYXS. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does PYXS stock do?

Preclinical/early clinical-stage biopharmaceutical company monetizing through strategic license/collaboration agreements while developing ADC and immuno-oncology therapies.

What is PYXS stock's price target?

This cached page does not contain a precise model fair value for PYXS.

The TradeMates model verdict for PYXS is AVOID with an investment score of 34/100. Treat this as a model signal to review, not a personal buy recommendation.

Is PYXS a good dividend stock?

PYXS is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

PYXS (PYXS) Stock Analysis

Q: Is PYXS stock a good investment?

The cached TradeMates AI model rates PYXS as AVOID with an investment score of 34/100. The model rates PYXS as AVOID due to severe cash burn (-$63.5M FCF) against limited cash reserves ($15.42M), making significant equity dilution virtually unavoidable before late-stage pipeline commercialization. This is algorithmic model output, not personal investment advice.

Verdict: AVOID

Imminent cash depletion and clinical trial binary risks overshadow pipeline potential, forcing high dilution probability before clinical inflection.

Investment score: 34/100

The model rates PYXS as AVOID due to severe cash burn (-$63.5M FCF) against limited cash reserves ($15.42M), making significant equity dilution virtually unavoidable before late-stage pipeline commercialization.

Peers

PRTC.L
IMRX
CYDY
ANIK
NWBO

Peer	P/E	P/B	P/S	EV/EBITDA	ROIC %	Net margin %
IMRX	-4.28	1.51	0.00	-2.02	—	0.00
CYDY	-5.83	-2.50	0.00	-7.32	—	0.00
ANIK	-78.16	2.06	2.34	98.20	—	-0.03
NWBO	-6.66	-7.80	124.86	-5.68	—	-17.36

View the full interactive analysis